AGC Biologics Partners with AAVantgarde for Gene Therapy Production

AGC Biologics has secured a significant manufacturing agreement with AAVantgarde to produce two investigational gene therapies aimed at treating inherited eye diseases. This collaboration leverages AGC Biologics’ innovative BravoAAV platform and a dual AAV vector approach, enhancing the potential for early and late-phase clinical manufacturing.

The agreement encompasses the Good Manufacturing Practice production of two gene therapy candidates: AAVB-039, which targets Stargardt disease, and AAVB-081, designed for retinitis pigmentosa linked to Usher syndrome type 1B. Both therapies are currently undergoing Phase 1/2 clinical development across the United States, United Kingdom, and Europe. These treatments aim to address progressive and irreversible vision loss, a condition for which no approved therapies are available.

Manufacturing Capabilities and Goals

The manufacturing will be conducted at AGC Biologics’ Milan Cell and Gene Center of Excellence, which specializes in both early and late-stage clinical supply. The facility has a proven track record of over 30 years and has received ten product approvals from the European Medicines Agency and the U.S. Food and Drug Administration.

The collaboration will utilize the BravoAAV suspension platform along with an innovative dual AAV vector methodology. This technique allows for the packaging of two halves of a gene separately, enabling reassembly within the target cell. This approach is particularly beneficial for delivering therapeutic genes that exceed the typical 4.7-kilobase vector capacity.

Strategic Partnership and Future Implications

AAVantgarde’s Chief Executive, Natalia Misciattelli, expressed enthusiasm about the partnership, stating, “We are delighted to partner with AGC Biologics, a world-class CDMO with deep expertise in viral vector manufacturing.” The agreement not only expands AGC Biologics’ role in the adeno-associated virus market but also enhances its capabilities across multiple vector types and stages of clinical development.

This partnership arises in the context of AAVantgarde’s recent Series B financing, which aims to bolster its research and development efforts in gene therapies. As the field of gene therapy continues to evolve, collaborations such as this are crucial for advancing treatments that could significantly improve the quality of life for patients suffering from inherited eye diseases.

With the ongoing clinical trials and technological advancements, AGC Biologics and AAVantgarde are positioned to make meaningful contributions to the fight against vision loss, potentially paving the way for new therapies in an area of significant unmet medical need.